13-valent pneumococcal polysaccharide conjugate vaccine (PCV13i) / Sinovac, CanSino 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    News 
  • ||||||||||  13-valent pneumococcal polysaccharide conjugate vaccine (PCV13i) / Sinovac, CanSino
    Clinical; Trial completion date; Trial primary completion date:  Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (clinicaltrials.gov) -  Aug 2, 2021   
    P1,  N=237, Active, not recruiting, 
    Trial completion date: Jun 2021 -> Dec 2021 | Trial primary completion date: May 2021 -> Sep 2021
  • ||||||||||  13-valent pneumococcal polysaccharide conjugate vaccine (PCV13i) / Sinovac, CanSino
    Clinical; Trial completion date; Trial primary completion date:  Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (clinicaltrials.gov) -  Nov 10, 2020   
    P1,  N=237, Active, not recruiting, 
    Trial completion date: Jun 2022 -> Jun 2021 | Trial primary completion date: Oct 2020 -> May 2021
  • ||||||||||  13-valent pneumococcal polysaccharide conjugate vaccine (PCV13i) / Sinovac, CanSino
    Clinical; New P1 trial:  Phase I Clinical Trial of One Vaccine (clinicaltrials.gov) -  Sep 18, 2019   
    P1,  N=237, Not yet recruiting,